| Description |
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research[1].
|
| Related Catalog |
|
| In Vitro |
KWAR 23 (0-1 μM; 4 h) shows antitumor activity of human neutrophil and macrophage[1]. KWAR 23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines[1]. Cell Viability Assay[1] Cell Line: Human macrophages and lymphoma cells Concentration: 0-1 μM Incubation Time: 4 h Result: Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23.
|
| In Vivo |
KWAR23 (intraperitoneal injection; 10 mg/kg; every other day; 21 d) exhibits effective antitumor activity in a human SIRPA knockin mouse model[1]. KWAR23 enhances neutrophil and macrophage antitumor activity in SRG Mice[1]. Animal Model: SIRPA knock-in mouse model injected with Burkitt’s lymphoma cells[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg; every other day; 21 d Result: Led to strong inhibition of tumor growth when combined with Rituximab.
|
| References |
[1]. Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585.
|
